Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug

Shares of Neurocrine Biosciences, Inc. (NBIX) soared 25% on Tuesday after announcing the FDA approval ofIngrezza (valbenazine) capsules a day before for the treatment of adults with tardive dyskinesia (TD).

    Allergan (AGN) Presents Mixed Depression Data on Botox

    Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

      Acorda (ACOR) to Reduce Workforce, Focus on Product Pipeline

      Acorda Therapeutics, Inc. (ACOR) recently announced plans to reduce its workforce by approximately 20%.

        Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst

        Celgene Corporation (CELG) recently received a Paragraph IV Notice Letter advising that Teva Pharmaceutical Industries Limited (TEVA) submitted an ANDA to the FDA seeking an approval to manufacture and market a generic version of Pomalyst.

          5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

          Lily carries a Zacks Rank #2 (Buy).

            Teva's Austedo Gets FDA Nod for Huntington Disease Treatment

            Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that the FDA has approved its investigational drug, Austedo (deutetrabenazine) tablets for the treatment of chorea associated with Huntington disease (HD).

              Allergan Acne Candidate Meets Endpoints in Phase III Studies

              Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline

                Teva Pharma Denies Rumors of Global Workforce Reduction

                According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.

                  Allergan's Restasis Now Available in Multidose Bottle in U.S.

                  Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.

                    Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod

                    Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.

                      Nektar's Pain Drug Positive in Phase III Study; Shares Gain

                      Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.

                        AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal

                        London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.

                          Teva Launches Authorized Generic of Allergan's Minastrin

                          Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.

                            What's Driving Lilly's (LLY) Shares after 2016 Decline?

                            After a rather difficult 2016, share price of pharma giant, Eli Lilly & Company (LLY) has picked up in 2017.

                              Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

                              Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

                                Teva (TEVA) Tops Q4 Earnings & Sales Estimates; Shares Up

                                Teva???s fourth quarter earnings (including equity compensation expenses), came in at $1.34 per share, beating consensus estimates of $1.32.

                                  David Bartosiak headshot

                                  Bartosiak: Trading Teva Pharmaceutical's (TEVA) Earnings with Options

                                  Join David Bartosiak to see his thoughts on Teva Pharma (TEVA) ahead of their earnings announcement, and he'll give us real time insight on how to play the options market.

                                    Kinjel Shah headshot

                                    Allergan (AGN) Tops Q4 Earnings; 2017 Sales View Upbeat

                                    Allergan plc's (AGN) fourth-quarter 2016 earnings came in at $3.90 per share, beating the Zacks Consensus Estimate of $3.79 by 2.9%.

                                      Teva (TEVA) Q4 Earnings: What's in Store for the Stock?

                                      Teva Pharmaceutical Industries Ltd. (TEVA) will be reporting fourth-quarter 2016 and full-year earnings on Feb 13, before the market opens.

                                        Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO

                                        Teva Pharmaceutical Industries Ltd. (TEVA) recently announced that its present chief executive officer (CEO), Erez Vigodman, is stepping down.

                                          Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q3

                                          Dr. Reddy's Laboratories Ltd. (RDY) reported third-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 42 cents, down 16% year over year.

                                            Allergan (AGN) Q4 Earnings: What's in Store for the Stock?

                                            Allergan plc (AGN) will be reporting fourth-quarter 2016 earnings on Feb 8, before the market opens. Last quarter, the company delivered a negative earnings surprise of 7.00%.

                                              Momenta Says District of Delaware Invalidates Teva's MS Drug

                                              Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter .

                                                Mylan (MYL) Gets Favorable Verdict for Copaxone in the US

                                                Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the company pertaining to claims related to Teva Pharmaceutical's (TEVA) Copaxone 40mg/mL.

                                                  Allergan (AGN) Avycaz Label to Include New Phase III Data

                                                  Allergan plc (AGN) announced that its supplemental new drug application (sNDA) for antibiotic Avycaz has been approved by the FDA. Allergan is looking to include new data from two phase III trials, RECAPTURE and REPRISE, in the drug???s label.